Ductal Carcinoma in Situ (DCIS) Clinical Trials and Research

Short placeholder heading

elizabeth-ann-mittendorf-and-staff653x447.jpg

The Dana-Farber Brigham Cancer Center team of breast cancer experts is dedicated to improving clinical care and advancing research for patients with ductal carcinoma in situ (DCIS). Our physician-scientists are engaged in multiple research studies to better understand the risk of progression to invasive disease and to better tailor treatment options to meet the needs of patients with DCIS.

Patients at Dana-Farber Brigham Cancer Center have access to leading-edge research and the opportunity to join clinical trials. Your team will discuss whether a clinical trial may be right for you. Together, we will advance the understanding of DCIS in order to provide more personalized treatment and prevention strategies for patients now and in the future.

Featured Clinical Trial

The PREDICT Registry
Principal Investigator: Tari A. King, MD

The primary objective of this study is to create a de-identified database of patients, test results, treatment decisions, and outcomes that can be queried to determine the clinical utility of the DCISionRT™ Test in the management of DCIS, as it is broadly incorporated into clinical practice.